Cannabidiol (CBD) is a cannabinoid found in cannabis. It is a major constituent of the plant, representing up to 40% in its extracts. Compared to THC, cannabidiol, though psychoactive, is non-intoxicating, and is considered to have a wider scope of medical applications than THC, including to epilepsy, multiple sclerosis spasms, anxiety disorders, schizophrenia, and nausea. Cannabidiol has displayed sedative effects in animal tests.
CBD is now being studied for use in the treatment of a large number of medical conditions.
Scientific and clinical research—much of it sponsored by the US government—underscores CBD’s potential as a treatment for a wide range of conditions, including arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, depression, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrable neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere. Further evidence suggests that CBD is safe even at high doses.
According to Wikipedia
Cannabidiol is a Schedule II drug in Canada. As such, it is only available with a prescription. It is available as a spray, called Sativex produced by GW Pharmaceuticals in the UK, for use in multiple sclerosis. The Canadian Government has passed its recreational legalization bill, which will come into effect on July 1, 2018, which will erase the necessity to obtain prescriptions for commercial CBD, as well as provision of cannabis federally to its citizens for recreational use.
Check the current status at : http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-13.html#h-29
Below are just a few of the many studies that hacve been conducted into the effects of CBD
Chron Valdez is a BC cannabis grower turned webslinger.